Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

ClinicalTrials.gov ID: NCT04913675

Public ClinicalTrials.gov record NCT04913675. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Multi-center, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Monoclonal Antibody VIR-7831 (Sotrovimab) Given Intramuscularly Versus Intravenously for the Treatment of Mild/Moderate Coronavirus Disease 2019 (COVID-19) in High-risk Non-hospitalized Patients; Safety Substudy Assessing the Safety and Tolerability of Single Ascending Dose Monoclonal Antibody VIR-7831

Study identification

NCT ID
NCT04913675
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Vir Biotechnology, Inc.
Industry
Enrollment
1,065 participants

Conditions and interventions

Conditions

Interventions

  • Sotrovimab Biological

Biological

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 9, 2021
Primary completion
Jul 18, 2022
Completion
Mar 23, 2023
Last update posted
Mar 6, 2024

2021 – 2023

United States locations

U.S. sites
48
U.S. states
15
U.S. cities
34
Facility City State ZIP Site status
Investigative Site Anniston Alabama 36207
Investigative Site Mesa Arizona 85210
Investigative Site Tucson Arizona 85712
Investigative Site Los Angeles California 90017
Investigative Site Rolling Hills Estates California 90274
Investigative Site Bradenton Florida 34208
Investigative Site Doral Florida 33126
Investigative Site Doral Florida 33166
Investigative Site Gainesville Florida 32607
Investigative Site Hialeah Florida 33012
Investigative Site Hialeah Florida 33013
Investigative Site Hialeah Florida 33016
Investigative Site Miami Florida 33032
Investigative Site Miami Florida 33125
Investigative Site Miami Florida 33126
Investigative Site Miami Florida 33135
Investigative Site Miami Florida 33144
Investigative Site Miami Florida 33155
Investigative Site Miami Florida 33175
Investigative Site Miami Florida 33176
Investigative Site Miami Florida 33180
Investigative Site North Miami Beach Florida 33169
Investigative Site Ormond Beach Florida 32174
Investigative Site Palmetto Bay Florida 33157
Investigative Sites Pembroke Pines Florida 33024
Investigative Site Pompano Beach Florida 33064
Investigative Site Tampa Florida 33614
Investigative Site Tampa Florida 33615
Investigative Site Atlanta Georgia 30318
Investigative Site Idaho Falls Idaho 83404
Investigative Site Mishawaka Indiana 46544
Investigative Site Sterling Heights Michigan 48126
Investigative Site Las Vegas Nevada 89113
Investigative Site The Bronx New York 10456
Investigative Site High Point North Carolina 27262
Investigative Site Mount Airy North Carolina 27030
Investigative Site Columbus Ohio 43215
Investigative Site Smithfield Pennsylvania 15478
Investigative Site Baytown Texas 77521
Investigative Site Forney Texas 75126
Investigative Site Houston Texas 77017
Investigative Site Houston Texas 77024
Investigative Site Houston Texas 77090
Investigative Site Laredo Texas 78041
Investigative Site Mesquite Texas 75149
Investigative Site Pharr Texas 78577
Investigative Site Kirkland Washington 98034
Investigative Site Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04913675, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 6, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04913675 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →